Methods and compositions for treating cancer

Patent metadata

Field	Value
Publication number	US-11033613-B2
Application number	US-201615777514-A
Country	US
Kind code	B2
Filing date	Nov 18, 2016
Priority date	Nov 20, 2015
Publication date	Jun 15, 2021
Grant date	Jun 15, 2021

Abstract

This invention provides methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, by administering a combination of at least one WT1 peptide, or cytotoxic T cells (CTLs) against a WT1-expressing cancer, and at least one checkpoint inhibitor. The at least one WT1 peptide can be administered to the subject by administering one or more agents to the subject resulting in delivery of one or more WT1 peptides and induction of an immune response against the WT1-expressing cancer. Examples of these WT1 delivery agents include: (i) an isolated WT1 peptide, (ii) a nucleic acid encoding the at least one WT1 peptide, and (iii) an immune cell comprising or presenting the at least one WT1 peptide or nucleic acid encoding the at least one WT1 peptide.

First claim

What is claimed is:

1. A method for treating, reducing the incidence of, or inducing an immune response against a WT1-expressing cancer, comprising administering to a human subject in need thereof (a) at least one WT1 peptide against a WT1-expressing cancer, and (b) at least one antibody checkpoint inhibitor that blocks or inhibits PD-1, wherein the at least one WT1 peptide is a combination of YMFPNAPYL (SEQ ID NO:124), RSDELVRHHNMHQRNMTKL (SEQ ID NO:1), PGCNKRYFKLSHLQMHSRKHTG (SEQ ID NO: 2) and SGQAYMFPNAPYLPSCLES (SEQ ID NO:125).

2. The method of claim 1 wherein (a) is administered with an adjuvant.

3. The method of claim 1 wherein the antibody checkpoint inhibitor is nivolumab, pembrolizumab, pidilizumab, MEDI0680 (AMP-514), or a combination of any of the foregoing.

4. The method of claim 1 wherein the cancer is ovarian cancer, mesothelioma, leukemia, Wilms' tumor, acute myelogenous leukemia (AML), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), melanoma, stomach cancer, prostate cancer, biliary cancer, urinary system cancer, glioblastoma, soft tissue sarcoma, osteosarcoma, or non-small cell lung cancer (NSCLC).

5. The method of claim 2 wherein the adjuvant is QS21, Montanide, Freund's complete or incomplete adjuvant, aluminum phosphate, aluminum hydroxide, BCG, a cytokine, or alum.

6. The method of claim 1 wherein 200 mcg of each peptide is emulsified with Montanide ISA 51 VG and administered subcutaneously on weeks 0, 2, 4, 6, 8 and 10.

7. The method of claim 3 wherein the antibody checkpoint inhibitor is nivolumab.

8. The method of claim 6 wherein 3 mg/kg of nivolumab is administered intravenously on weeks 0, 2, 4, 6, 8, 10 and 12.

9. The method of claim 1 wherein the treating, reducing the incidence of, or inducing an immune response against a WT1-expressing cancer is greater than achieved by administering the at least one WT1 peptide alone or the antibody checkpoint inhibitor that blocks or inhibits PD-1 alone.

10. The method of claim 1 , wherein the cancer is ovarian cancer and (a) and (b) are administered after completion of chemotherapy.

11. The method of claim 1 , wherein the subject is in remission.

12. The method of claim 1 , wherein the cancer is ovarian cancer and the antibody checkpoint inhibitor is nivolumab.

Assignees

• Memorial Sloan Kettering Cancer Center

Inventors

• Scheinberg David

Classifications

• A61K2039/505

  comprising antibodies · CPC title

• A61K2039/5158

  Antigen-pulsed cells, e.g. T-cells · CPC title

• A61K2039/5154

  Antigen presenting cells [APCs], e.g. dendritic cells or macrophages · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K39/3955 Primary

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title